Non-Hodgkin lymphoma incidence statistics

Cases

New cases of non-Hodgkin lymphoma, 2015, UK

 

Proportion of all cases

Percentage non-Hodgkin lymphoma is of total cancer cases, 2015, UK

 

Age

Peak rate of non-Hodgkin lymphoma cases, 2013-2015, UK

Trend over time

Change in non-Hodgkin cancer incidence rates since the early 1990s, UK

Non-Hodgkin lymphoma is the 6th most common cancer in the UK, accounting for 4% of all new cancer cases (2015).[1-4]

In males in the UK, non-Hodgkin lymphoma is the 7th most common cancer (4% of all new male cancer cases). In females in the UK it is the 7th most common cancer (4% of all new female cancer cases).

55% of non-Hodgkin lymphoma cases in the UK are in males, and 45% are in females.

Non-Hodgkin lymphoma incidence rates (European age-standardised (AS) rates Open a glossary item ) for persons are significantly lower than the UK average in Scotland and Wales, and similar to the UK average in all other UK constituent countries.

Non-Hodgkin Lymphoma (C82-C86), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2015

  England Scotland Wales Northern Ireland UK
Male Cases 6,427 529 344 178 7,478
Crude Rate 23.8 20.3 22.5 19.6 23.3
AS Rate 27.5 22.8 23.6 24.8 26.9
AS Rate - 95% LCI 26.9 20.9 21.1 21.2 26.2
AS Rate - 95% UCI 28.2 24.8 26.1 28.4 27.5
Female Cases 5,263 499 295 147 6,204
Crude Rate 19.0 18.1 18.7 15.6 18.8
AS Rate 19.6 17.8 17.7 17.0 19.3
AS Rate - 95% LCI 19.1 16.3 15.7 14.3 18.8
AS Rate - 95% UCI 20.1 19.4 19.7 19.8 19.7
Persons Cases 11,690 1,028 639 325 13,682
Crude Rate 21.3 19.1 20.6 17.6 21.0
AS Rate 23.2 20.1 20.4 20.7 22.7
AS Rate - 95% LCI 22.8 18.8 18.8 18.4 22.4
AS Rate - 95% UCI 23.6 21.3 21.9 22.9 23.1

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item  around the AS Rate Open a glossary item
 

For non-Hodgkin lymphoma, there are few established risk factors therefore differences between countries largely reflect differences in diagnosis and data recording.

References

  1. Data were provided by the Office for National Statistics on request, July 2017. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, August 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, October 2017. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, July 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015, ICD-10 C82-C86.

The term 'non-Hodgkin lymphoma' describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the variation between these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Non-Hodgkin lymphoma incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2013-2015, on average each year more than a third (35%) of new cases were in people aged 75 and over.[1-4

Age-specific incidence rates rise steadily from around age 45-49 and more steeply from around age 55-59. The highest rates are in the 85 to 89 age group for males and the 80 to 84 age group for females.

Incidence rates are significantly higher in males than females in most age groups. The gap is widest at age 0 to 04, when the age-specific incidence rate is 3.5 times higher in males than females.

Non-Hodgkin Lymphoma (C82-C86), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2013-2015

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item
 

For non-Hodgkin lymphoma, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

The term ‘non-Hodgkin lymphoma’ describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the heterogeneity of these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

References

  1. Data were provided by the Office for National Statistics on request, July 2017. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, August 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, October 2017. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, July 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

 

About this data

Data is for UK, 2013-2015, ICD-10 C82-C86.

Last reviewed:

Non-Hodgkin lymphoma European age-standardised (AS) Open a glossary item incidence rates for males and females combined increased by 39% in the UK between 1993-1995 and 2013-2015.[1-4] The increase was of a similar size in males and females.

For males, non-Hodgkin lymphoma AS incidence rates in the UK increased by 36% between 1993-1995 and 2013-2015. For females, non-Hodgkin lymphoma AS incidence rates in the UK increased by 40% between 1993-1995 and 2013-2015.

Over the last decade in the UK (between 2003-2005 and 2013-2015), non-Hodgkin lymphoma AS incidence rates for males and females combined increased by 16%. In males AS incidence rates increased by 17%, and in females rates increased by 15%.

Non-Hodgkin Lymphoma (C82-C86), European Age-Standardised Incidence Rates, UK, 1993-2015

Non-Hodgkin lymphoma incidence rates have increased overall in some broad age groups in males and females combined in the UK since the early 1990s, but have remained stable in others.[1-4] Rates in 0-24s have remained stable, in 25-49s have remained stable, in 50-59s have increased by 12%, in 60-69s have increased by 42%, in 70-79s have increased by 55%, and in 80+s have increased by 66%.

Non-Hodgkin Lymphoma (C82-C86), European Age-Standardised Incidence Rates, By Age, UK, 1993-2015

For non-Hodgkin lymphoma, like most cancer types, incidence trends largely reflect changing prevalence of risk factors and improvements in diagnosis and data recording. Recent incidence trends are influenced by risk factor prevalence in years past, and trends by age group reflect risk factor exposure in birth cohorts.

References

  1. Data were provided by the Office for National Statistics on request, July 2017. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, August 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, October 2017. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, July 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1993-2015, ICD-10 C82-C86.

Last reviewed:

Staging completeness for non-Hodgkin lymphoma is moderate in England, with 78% of non-Hodgkin lymphoma cases recorded with a known stage at diagnosis in 2014.[1]

Non-Hodgkin Lymphoma (C82-C85), Proportion of Cases Diagnosed at Each Stage, England 2014

People diagnosed with non-Hodgkin lymphoma with a known stage most commonly present at stage IV (45%), in England. More people with a known stage are diagnosed at an advanced stage (64% diagnosed at stage III or IV) than an early stage (36% diagnosed at stage I or II ).[1]

References

  1. National Cancer Registration and Analysis Service. Stage Breakdown by CCG 2014. London: NCRAS; 2016.

About this data

Data is for: England, 2014, ICD-10 C82-C85

Stage at diagnosis data is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past.

Last reviewed:

Non-Hodgkin lymphoma (NHL) incidence rates are projected to fall by 2% in the UK between 2014 and 2035, to 26 cases per 100,000 people by 2035.[1] This includes a smaller decrease for males than for females.

For males, non-Hodgkin lymphoma European age-standardised (AS) Open a glossary item incidence rates in the UK are projected to fall by 3% between 2014 and 2035, to 32 cases per 100,000 by 2035.[1] For females, rates are projected to fall by 3% between 2014 and 2035, to 22 cases per 100,000 by 2035.[1]

Non-Hodgkin lymphoma (C82-C85), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

 

It is projected that 18,621 cases of non-Hodgkin lymphoma (10,489 in males, 8,132 in females) will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C82-C85

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

The lifetime risk of developing non-Hodgkin lymphoma (NHL) (all subtypes combined) is 1 in 48 for men and 1 in 58 for women, in 2012 in the UK.[1]

The lifetime risk for NHL has been calculated on the assumption that the possibility of having more than one diagnosis of NHL over the course of a lifetime is very low (‘Current Probability’ method).[2]

References

  1. Lifetime risk estimates calculated by the Statistical Information Team at Cancer Research UK. Based on data provided by the Office of National Statistics, ISD Scotland, the Welsh Cancer Intelligence and Surveillance Unit and the Northern Ireland Cancer Registry, on request, December 2013 to July 2014.
  2. Esteve J, Benhamou E and Raymond L. Descriptive epidemiology. IARC Scientific Publications No.128, Lyon, International Agency for Research on Cancer, pp 67-68 1994.
Last reviewed:

There is evidence for a small association between non-Hodgkin lymphoma (NHL) incidence and deprivation for females in England, but there is no evidence for an association for males.[1] England-wide data for 2006-2010 show European age-standardised Open a glossary item incidence rates are 6% higher for females living in the most deprived areas compared with the least deprived, but for males the rates are similar for those living in the least and most deprived areas.[1]

Non-Hodgkin Lymphoma (C82-C85), European Age-Standardised Incidence Rates by Deprivation Quintile, England, 2006-2010

For males diagnosed with non-Hodgkin lymphoma the deprivation gradient has gone from having higher incidence rates in the less deprived in 1996-2000 to having higher incidence rates in the more deprived in 2006-2010. The estimated deprivation gradient in non-Hodgkin lymphoma incidence between people living in the most and least deprived areas in England has not changed in the period 1996-2010.

It has been estimated that there would have been around 50 more cancer cases each year amongst males in England during 2006-2010 if all males experienced the same incidence rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for UK, 2006-2010, ICD-10 C82-C85

Deprivation gradient statistics were calculated using incidence data for 2006-2010. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Age-standardised Open a glossary item rates for White males with Non-Hodgkin lymphoma (ICD-10 C82-C85 and C96) range from 15.7 to 16.5 per 100,000. Rates for Asian males are similar, ranging from 10.3 to 16.9 per 100,000 and the rates for Black males are also similar, ranging from 11.4 to 19.6 per 100,000. For females there is a similar pattern - the age-standardised rates for White females range from 11.2 to 11.8 per 100,000 and rates for Asian and Black females are also similar ranging from 7.0 to 11.8 per 100,000 and 8.7 to 15.1 per 100,000 respectively.[1]

There appears to be no significant variation in Non-Hodgkin lymphoma incidence by ethnicity in the UK.[1,2] However, US data shows that since 1992, NHL rates have been significantly higher in non-Hispanic white people than in black people.[3]

Ranges are given because of the analysis methodology used to account for missing and unknown data. For Non-Hodgkin lymphoma, 42,576 cases were identified; 21% had no known ethnicity.

References

  1. National Cancer Intelligence Network (NCIN) and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. London: NCIN; 2009.
  2. Ross JRY, Oliver SE. National Cancer Intelligence Network (NCIN) analyses of haematological malignancy. Incidence and survival by sex, ethnicity, deprivation, year of diagnosis and cancer network in the United Kingdom. Brit J Haematol 2010;149:57.
  3. Surveillance Epidemiology and End Results. Age-Adjusted SEER Incidence Rates and 95% Confidence Intervals; By Race/Ethnicity; Non-Hodgkin Lymphoma, All Ages, Both Sexes; 1992- 2009. Accessed at: http://seer.cancer.gov. Accessed September 2012.
Last reviewed:

An estimated 76,800 people who had been diagnosed with non-Hodgkin lymphoma (NHL) between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 C82-C86

Last reviewed:

Non-Hodgkin lymphoma (NHL) (C82-C85 and C96) is the 11th most common cancer in Europe, with around 93,500 new cases diagnosed in 2012 (3% of the total). In Europe (2012), the highest World age-standardised Open a glossary item incidence rates for NHL are in Italy for men and the Netherlands for women; the lowest rates are in Albania for both men and women. UK NHL incidence rates are estimated to the ninth highest in males in Europe, and eighth highest in females.[1] These data are broadly in line with Europe-specific data available elsewhere.[2]

NHL (C82-C85 and C96) is the tenth most common cancer worldwide, with nearly 386,000 new cases diagnosed in 2012 (3% of the total). NHL incidence rates are highest in Northern America and lowest in South Central Asia, but this partly reflects varying data quality worldwide.[1]

Variation between countries may reflect different prevalence of risk factors, use of screening, and diagnostic methods.

References

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:http://globocan.iarc.fr, accessed December 2013.
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer (2013) 49, 1374-1403.

About this data

Data is for: Europe and worldwide, 2012, ICD-10 C82-C85 and C96

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 2.4 out of 5 based on 10 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page